Discovery of genetic modification factor for breast cancer treatment

Australian researchers have discovered a gene mutation that could open up new treatment options for breast cancer patients.

The factor is the molecule ELF5, which allows doctors to transform cancer cells, making treatments such as anti-oestrogens more effective.

Research results from experts at the Garvan Institute of Medical Research in Sydney show that the ELF5 molecule can cause gene cells to be activated or deactivated.

Illustration photo. (Source: bacsivn.com)

By manipulating these molecules, the sensitivity of breast cancer cells to anti-estrogen therapy was significantly increased.

"ELF5 molecules determine how cancer cells respond to anti-estrogen therapy," said Professor Chris Ormandy.

This discovery has demonstrated for the first time the interaction between the ELF5 molecule and breast cancer. Previously, this molecule was discovered by Professor Ormandy's research group to be present in all breast cancer cells since 1999.

By 2008, this same group had also demonstrated that ELF5 stimulates lactation in women.

The discovery is expected to open up the prospect of developing a specific drug to help destroy cancer cells. Breast cancer patients could also avoid the risk of having to use other toxic treatments such as chemotherapy.

Breast cancer is the most common cancer and the second leading cause of cancer death in women.

In 2008, Australia had 13,600 breast cancer patients and after 5 years of treatment, the survival rate was 89%./.

According to (TTXVN) - VT